Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06227819 · ClinicalTrials.gov registry record
BVA-200 vs BVA-100 Validation Study
A clinical trial of Heart Failure and Diabetes, sponsored by Daxor Corporation.
- Completed
- Registry status
- 62
- Enrollment target
- 1
- Study location
NCT06227819 is a study of Heart Failure and Diabetes that has completed, run by Daxor Corporation. The registered enrollment target is 62 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06227819, a study of Heart Failure and Diabetes, has completed, sponsored by Daxor Corporation.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device. Data from this study may be pooled with data from studies with similar design conducted at other sites, for the purposes of an FDA medical device submission.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST BVA-200
Study Locations (1)
Tennessee
- Daxor Corporation - Oak Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2023-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06227819
The ClinicalTrials.gov registry entry for NCT06227819 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Daxor Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which BVA-200 is the first listed.
NCT06227819 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06227819 about?
NCT06227819 is a clinical study titled "BVA-200 vs BVA-100 Validation Study". The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device. Data from this study may be pooled with data from studies with similar design conducted...
What is the current status of trial NCT06227819?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2023-05-23. Estimated completion is 2023-11-30.
What conditions does trial NCT06227819 study?
This clinical trial studies the following conditions: Heart Failure, Diabetes, Anemia, Trauma, Kidney Diseases.
What interventions are being tested in trial NCT06227819?
The interventions under investigation include: BVA-200 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06227819?
This trial is sponsored by Daxor Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06227819 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.